echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Kanghong Pharmaceutical's Conbercept ophthalmic injection was approved for clinical use

    Kanghong Pharmaceutical's Conbercept ophthalmic injection was approved for clinical use

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 4th, Kanghong Pharmaceutical issued an announcement stating that its wholly-owned subsidiary had recently received the "Drug Clinical Trial Approval Notice" for Conbercept ophthalmic injection issued by the State Food and Drug Administration, and agreed to carry out clinical trials
    .
    It is reported that the product can bind to VEGF in blood vessels and tissues and block the signal transmission that promotes the sprouting and growth of new blood vessels mediated by VEGF


    .


    Conbercept ophthalmic injection was approved in 2013 for the treatment of wet age-related macular degeneration (nAMD), and in 2017 it was approved for the treatment of visual impairment (pmCNV) secondary to pathological myopia caused by choroidal neovascularization.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.